Skip to main content
Premium Trial:

Request an Annual Quote

Accelrys, Agilent, Yale University, Biotique, GATC Biotech, Genome Explorations

Accelrys, Agilent Partner to Resell Each Other's Software to Pharma
Accelrys and Agilent Technologies said this week that they have struck an agreement to resell each other's software to pharmaceutical companies through an integration and licensing partnership.
Under the agreement, Accelrys will resell Agilent's OpenLAB enterprise content manager, Kalabie electronic lab notebook, and GeneSpring gene expression software. Agilent will resell Accelrys' Accord cheminformatics solutions and Pipeline Pilot scientific operating platform.
"Agilent's strength in laboratory Informatics, QA/QC, and manufacturing are a natural complement to Accelrys' expertise in research, early development, and scientific data management," said Accelrys CEO Mark Emkjer.
Agilent's vice president and general manager, Bruce von Herrmann, said the integrated license and joint resale deal will benefit pharmaceutical clients "that want to spend less time integrating existing informatics solutions and more time developing new, more effective medicines."
Financial terms of the agreement were not released.

Yale University Adopts Biotique’s XRAY Array Analysis Software
Biotique Systems this week said that Yale University has licensed its XRAY gene expression analysis software for analyzing Affymetrix microarrays.
According to Biotique, XRAY enables users to perform normalization and analysis on large sets of Affymetrix arrays, find differential gene expression and alternative splicing with exon and gene arrays, and identify potential binding regions with Affymetrix tiling arrays.
Shrikant Mane, director of the Microarray Resource at the W.M. Keck Foundation Biotechnology Resource Laboratory at Yale University called XRAY an “intuitive and powerful tool for the analysis of Affymetrix exon array data” in a statement.
Financial details of the deal were not discussed.

GATC to Coordinate International Sepsis-Pathogen Dx Project
GATC Biotech said this week that it is coordinating an international effort to develop a microarray-based diagnostics test for bacterial and fungal pathogens that trigger sepsis.
GATC, based in Constance, Germany, said that it will function as the coordinating partner for project, which includes the Fraunhofer Institute in Germany and the National University of Pusan and Gene In Corporation, which are both located in South Korea.
The German Federal Ministry of Education, Science, Research and Technology will put up some of the funds for the research, the company added.
Each year, there are around 18 million cases of sepsis in the world, and between 28 percent and 50 percent of these infections are fatal, according to the company. GATC said the global financial cost of these illnesses total an estimated €7.6 billion ($10.7 billion).
The proposed diagnostic would “enable the immediate detection of organism-specific nucleic acid sequences, offering the advantage of reducing the time between sample collection and diagnosis, leading to a reduction in mortality rates,” the company said.
A timeline for completion of the diagnostic was not provided.

Genome Explorations Wins $830K SBIR Award for Biomarker Research
Genome Explorations has received an $830,000 Small Business Innovation Research grant from the National Institute of Alcohol Abuse and Addiction for alcohol-related biomarker research.
The company said it will use the Affymetrix microarray platform to develop “more sensitive and informative” biomarkers for chronic alcohol use and alcohol-induced organ damage to enable early detection of pathologies related to alcoholism.
Some of the research will be conducted at the company’s lab in Memphis, Tenn., and some will be conducted at the University of Tennessee Health Sciences Center.

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.